Avaforce 100 mg contains Avanafil, a phosphodiesterase type 5 (PDE5) inhibitor primarily used to treat erectile dysfunction. Although it is not the first-line treatment for pulmonary arterial hypertension (PAH), drugs in the same class—like sildenafil and tadalafil—are approved for this condition due to their vasodilatory effects on the pulmonary arteries.
Avanafil works by inhibiting the PDE5 enzyme found in the smooth muscle of blood vessels, including those in the lungs. Inhibition of this enzyme increases levels of cyclic guanosine monophosphate (cGMP), which leads to relaxation of the pulmonary vascular smooth muscle and reduced pulmonary arterial pressure. This improves blood flow through the lungs and decreases the workload on the right side of the heart.
While AVAFORCE 100 MG is not officially approved for pulmonary hypertension, it has a theoretical role similar to other PDE5 inhibitors in off-label scenarios. Its rapid onset and shorter duration may offer some benefit, but its use in PAH should be under strict medical supervision and preferably replaced by PDE5 inhibitors that are clinically validated for PAH, such as Revatio (sildenafil) or Adcirca (tadalafil).
Therefore, Avaforce 100 mg is not standard therapy for pulmonary hypertension but represents a pharmacologically relevant agent in the same drug class.
Add your comment